A new stem cell therapy focused on age-associated frailty has seen success in its first two human trials. The treatment extracted adult stem cells called mesenchymal stem cells, or MSC, from bone marrow and infused them into patients with an average age of 76. The main purpose of these trials was to test for safety, and both phases showed no …